Therapeutic options in the management of chronic heart failure. Is there a drug of first choice?
Packer
M
M
Department of Medicine, Mount Sinai School of Medicine, City University of New York, New York.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002908:Chronic Disease; D004070:Digitalis; D004232:Diuretics / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D010946:Plants, Medicinal; D010947:Plants, Toxic; D014665:Vasodilator Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D004232:Diuretics; D010726:Phosphodiesterase Inhibitors; D014665:Vasodilator Agents